Accelerated middle half body radiotherapy in bone metastases from prostate cancer: A phase I study (SHARON project)

Francesco Cellini, Francesco Deodato, Gabriella Macchia, Savino Cilla, Alessio Giuseppe Morganti, Alice Zamagni, Milly Buwenge, Giambattista Siepe, Alessandra Arcelli, Eleonora Farina, Silvia Cammelli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background/Aim: The primary endpoint of this phase I study was the maximum tolerated dose (MTD) of middle half body (MHB) accelerated radiotherapy (RT) in multiple bone metastatic (BM) prostate cancer (PCa) patients. Patients and Methods: Three step dose escalation [13 Gy (3.25 Gy/fraction), 14 Gy (3.5 Gy/fraction), and 15 Gy (3.75 Gy/fraction)] in three consecutive patient cohorts were planned. RT was delivered in two consecutive days and two daily fractions. Six patients were enrolled in the first two cohorts and 12 in the third cohort. Grade ≥3 toxicity was considered as a dose-limiting toxicity (DLT). Results: Twenty-five patients (median age=71 years, median followup=7.4 months) were enrolled. Defined MTD dose was 15 Gy. Overall pain response rate was 76%: 9 patients (36%) showed complete and 10 patients (40%) reported partial response of pain. Conclusion: MHB accelerated RT (total dose: 15 Gy) delivered in two consecutive days and two daily fractions is well tolerated.
Lingua originaleEnglish
pagine (da-a)5065-5069
Numero di pagine5
RivistaAnticancer Research
Volume39
DOI
Stato di pubblicazionePubblicato - 2019

Keywords

  • Bone metastases
  • Radiotherapy
  • Phase I
  • Prostate neoplasm
  • Aged
  • Bone Neoplasms
  • Combined Modality Therapy
  • Follow-Up Studies
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Prostatic Neoplasms
  • Quality of Life
  • Radiotherapy Dosage
  • Treatment Outcome
  • Palliative therapy

Fingerprint

Entra nei temi di ricerca di 'Accelerated middle half body radiotherapy in bone metastases from prostate cancer: A phase I study (SHARON project)'. Insieme formano una fingerprint unica.

Cita questo